Pathogenesis And Course Of Cutaneous T-Cell Lymphoma
- Follow the disease course of patients with cutaneous T-cell lymphoma.
- Provide a patient population for study by proteomic and molecular analysis.
- Develop a mechanism for screening by a Tumor Board for enrollment of patients in
therapeutic clinical trials.
- Develop a tissue bank for future disease study using specimens from these patients.
- Provide community outreach by offering a second opinion regarding treatment of this
disease in these patients and, in limited cases, provide standard-of-care treatment to
- Develop an algorithm for screening and evaluating this disease in these patients.
OUTLINE: Patients undergo disease assessment by physical examination, full-body photographic
documentation of skin disease, biopsy, and blood sampling at baseline and then at least
annually thereafter. Proteomic and molecular methods are used to analyze samples. Biopsies
may be examined using histologic and immunohistochemical methods. Blood may be analyzed by
polymerase chain reaction for clonal T-cell gene rearrangements or by flow cytometry.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 5 years.
Disease course of patients with cutaneous T-cell lymphoma (CTCL)
Mark C. Udey, MD, PhD
NCI - Dermatology Branch
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office||Bethesda, Maryland 20892-1182|